hypereosinophilic syndrome
AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome
April 4, 2019Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
